Details for Patent: 7,078,394

Title:	Low dose estrogen interrupted hormone replacement therapy
Abstract:	A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 .mu.g per day of norgestimate.
Inventor(s):	Casper; Robert F. (Toronto, CA), Shangold; Gary A. (Califon, NJ), Ausmanas; Militza K. (Lake Forest, IL)
Assignee:	Duramed Pharmaceuticals, Inc. (Pomona, NY)
Filing Date:	Mar 22, 2004
Application Number:	10/806,613
Claims:	1. A method of treating a female in need of hormone replacement therapy, the method comprising administering a medicament comprising a plurality of doses for consecutive administration in alternating phases, which phases consist of a relatively dominant estrogenic activity phase comprising three consecutive daily doses or an equivalent thereof, of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol, and a relatively dominant progestogenic activity phase comprising three daily doses or an equivalent thereof, of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 .mu.g per day of norgestimate to the female in need of treatment. 2. The method of claim 1 in which the daily doses in the relatively dominant estrogenic activity phase comprise about 1 mg per day of 17.beta.-estradiol, and in the relatively dominant progestogenic activity phase comprise about 1 mg per day of 17.beta.-estradiol and about 90 .mu.g per day of norgestimate. 3. The method of claim 2 wherein the doses are in oral form. 4. The method of claim 3 wherein the doses are in tablet form.